

Brandes Investment Partners

Global Opportunities Value Strategy Notes Second Quarter 2024 (April 1 – June 30, 2024)

The Brandes Global Opportunities Value Strategy rose 1.53% net of fees and 1.74% gross of fees, underperforming its benchmark, the MSCI ACWI Index, which rose 2.87% in the guarter.

Annualized total return as of June 30, 2024	1-year	5-year	10-year
Brandes Global Opportunities Value Composite (net)	26.47%	9.19%	4.40%
Brandes Global Opportunities Value Composite (gross)	27.57%	10.21%	5.33%
MSCI ACWI Index	19.38%	10.74%	8.43%

Past performance is not a guarantee of future results. One cannot invest directly in an index. Returns include reinvestment of all dividends and are reduced by any applicable foreign withholding taxes, without provisions for income taxes, if any.

Positive Contributors

Holdings in financials aided performance, led by Spanish insurer Linea Directa Aseguradora, Slovenian Nova Ljubljanska Banka, Austria-domiciled Erste Group Bank, and U.K.-based NatWest.

Taiwan Semiconductor Manufacturing Company (TMSC) and Hong Kong-based textile company Yue Yuen were also standout contributors. Yue Yuen's shares surged nearly 50% after the company reported improved order visibility and better-than-expected earnings fueled by multi-year-high margins. Meanwhile, TSMC received Taiwanese government approval to finance the construction of manufacturing facilities in Japan and the U.S., positioning it to support the growing demand for artificial intelligence and high-performance computing technologies.

Other notable contributors included select holdings in communication services, such as Hungary's Magyar Telekom and Luxembourg-domiciled Millicom International Cellular. Geographically, the portfolio benefited the most from holdings in the United Kingdom. In addition to NatWest, tobacco manufacturer Imperial Brands and real estate firm LSL Property Services lifted returns, along with facility management company MITIE Group and media firm ITV.

Performance Detractors

Technology represented the best-performing component of the benchmark, and our significant underweight to the sector was the largest detractor from relative returns.

Other notable detractors included several holdings in health care, such as U.S. Elanco Animal Health, U.K.-based GSK, and Japan's Kissei Pharmaceutical. GSK's shares fell after a U.S. public health agency narrowed its age recommendation for RSV (respiratory syncytial virus) vaccines, limiting the use of the company's products.

Geographically, Mexico was among the worst-performing markets in the benchmark as the presidential election results led to investor concerns about the potential for less market-friendly policies by the new government. Several of our holdings were impacted by the negative market sentiment, most notably real estate investment trusts Fibra Uno and Fibra Macquarie Mexico, as well as cement manufacturer Cemex. Moreover, our overweight hurt relative returns.

Amid the macroeconomic challenges, we maintain confidence in the company fundamentals of our holdings in Mexico. In our opinion, they are well managed, with low susceptibility to government intervention and long histories navigating turbulent times.

In addition to Mexico, exposure to Brazil diminished returns, led by positions in Telefonica Brasil and beverage firm Ambev.



Select Activity in the Quarter

The investment committee initiated positions in France-based luxury goods firm Kering and Canadian aerospace and defense company CAE, while divesting holdings in Spanish Atresmedia and U.S.-based construction engineering firm Orion Group.

Our coverage of CAE began in 2011, and since then, our assessment of the company's core franchise quality remains unchanged. With its dominant position in flight simulation and pilot training, CAE has historically generated solid free cash flow and healthy returns on invested capital. The company also benefits from its access to attractive financing sources in the form of perpetual zero-cost loans from the Canadian government for research and development initiatives.

It is notable that during the COVID-19 pandemic, CAE took significant steps to strengthen its competitive position and improve industry structure. Firstly, the company leveraged its financial strength to complete a series of opportunistic acquisitions, purchasing nine companies at what we deemed depressed prices. This has helped CAE consolidate end-markets and expand capabilities. Secondly, it restructured its cost base, closing nine plants and removing U.S.\$70 million in annualized costs that resulted in a 1.5% margin benefit on sales. Lastly, CAE expanded its relationship with mainline airlines, which chose to outsource an increasing share of their internal training needs. To satisfy this new demand, CAE embarked on a heavy capital expenditure cycle over the course of the pandemic that we believe will benefit shareholders in the years ahead.

The opportunity to initiate a position in CAE came as investors have been concerned about recent margin weakness in the defense segment. However, we view these challenges as temporary. Inflation and supply chain pressures have started to ease, and many of CAE's under-earning, fixed-priced contracts are set to expire by 2025. We expect that CAE is positioned to improve its profitability as legacy fixed-priced contracts roll over and new high-margin defense contracts begin to ramp up. Based on the company's guidance, new contracts should earn mid-double-digit margins, compared to the mid-single-digit margins on the legacy fixed-priced contracts that were impacted by the pandemic-related cost pressures. At its current valuation levels, CAE represents an appealing risk/reward tradeoff to us.

Year-to-Date Briefing

The Brandes Global Opportunities Value Strategy rose 10.34% net of fees and 10.81% gross of fees, underperforming its benchmark, the MSCI ACWI Index, which appreciated 11.30% in the six months ended June 30, 2024.

Holdings in industrials and financials drove performance, led by Rolls-Royce and Embraer in industrials, and Banco Latinoamericano, Linea Directa Aseguradora, and Nova Ljubljanska Banka in financials. Select technology holdings also showed robust results, specifically TSMC, SAP, and Arlo Technologies. Similar to the quarter, Yue Yuen was a solid contributor, as were Magyar Telekom and Millicom International Cellular.

Several holdings in health care weighed on performance, most notably Spanish biotech firm Grifols and Japanese Takeda Pharmaceutical and Kissei Pharmaceutical. Grifols declined mainly in the first quarter following a short seller's report that questioned the company's debt and corporate governance practices. We continue to believe there is a meaningful upside potential in Grifols. The company recently completed the sale of an ownership stake in Shanghai RAAS, which should help it improve its financial leverage in the near term.

Geographically, our underweight to the U.S. hurt relative returns, along with our overweight to emerging markets, particularly to Mexico and Brazil.

Current Positioning

The portfolio positioning has largely remained unchanged. The strategy continues to have large overweight positions in communication services, real estate, and consumer staples, while retaining a significant underweight to technology. On a regional basis, it maintains overweights to emerging markets, the United Kingdom, France, and Spain, while remaining underweight the U.S., which accounts for nearly 65% of the benchmark.



We believe the differences between our portfolio and the MSCI ACWI Index make it an appealing complement to index-tracking or passively managed strategies. Going forward, we remain optimistic about the portfolio's holdings composition and the risk/reward tradeoff it offers.

Term definitions: https://www.brandes.com/termdefinitions

The MSCI ACWI with net dividends captures large and mid cap representation of developed and emerging markets.

MSCI has not approved, reviewed or produced this report, makes no express or implied warranties or representations and is not liable whatsoever for any data in the report. You may not redistribute the MSCI data or use it as a basis for other indices or investment products.

The foregoing Quarterly Commentary reflects the thoughts and opinions of Brandes Investment Partners® exclusively and is subject to change without notice. The information provided in the commentary should not be considered a recommendation to purchase or sell any particular security. It should not be assumed that any security transactions, holdings or sectors discussed were or will be profitable, or that the investment recommendations or decisions we make in the future will be profitable or will equal the investment performance discussed herein. International and emerging markets investing is subject to certain risks such as currency fluctuation and social and political changes; such risks may result in greater share price volatility. There is no assurance that any securities discussed herein will remain in an account's portfolio at the time you receive this report or that the securities sold have not been repurchased. The actual characteristics with respect to any particular account will vary based on a number of factors including but not limited to: (i) the size of the account; (ii) investment restrictions applicable to the account, if any, and (iii) market exigencies at the time of investment. Unlike bonds issued or guaranteed by the U.S. government or its agencies, stocks and other bonds are not backed by the full faith and credit of the United States. Stock and bond prices will experience market fluctuations. Please note that the value of government securities and bonds in general have an inverse relationship to interest rates. Bonds carry the risk of default, or the risk that an issuer will be unable to make income or principal payment. There is no assurance that private quarantors or insurers will meet their obligations. The credit quality of the investments in the portfolio is not a guarantee of the safety or stability of the portfolio. Investments in Asset Backed and Mortgage Backed Securities include additional risks that investors should be aware of such as credit risk, prepayment risk, possible illiquidity and default, as well as increased susceptibility to adverse economic developments. Securities of small companies generally experience more volatility than mid and large sized companies. Although the statements of fact and data in this report have been obtained from, and are based upon, sources that are believed to be reliable, we cannot quarantee their accuracy, and any such information may be incomplete or condensed. Strategies discussed are subject to change at any time by the investment manager in its discretion due to market conditions or opportunities. The Brandes investment approach tends to result in portfolios that are materially different than their benchmarks with regard to characteristics such as risk, volatility, diversification, and concentration. Please note that all indices are unmanaged and are not available for direct investment. Past performance is not a quarantee of future results. No investment strategy can assure a profit or protect against loss. Market conditions may impact performance. The performance results presented were achieved in particular market conditions which may not be repeated. Moreover, the current market volatility and uncertain regulatory environment may have a negative impact on future performance. The margin of safety for any security is defined as the discount of its market price to what the firm believes is the intrinsic value of that security. The declaration and payment of shareholder dividends are solely at the discretion of the issuer and are subject to change at any time.

United States: Issued by Brandes Investment Partners, L.P., 4275 Executive Square, 5th Floor, La Jolla, CA 92037.

Singapore/Asia: FOR INSTITUTIONAL/ACCREDITED INVESTOR USE ONLY. Issued by Brandes Investment Partners (Asia) Pte Ltd., The Gateway West, 150 Beach Road, #35-51, Singapore 189720. Company Registration Number 201212812M. ARBN:164 952 710. This document is for "institutional investors" or "accredited investors" as defined under the Securities and Futures Act, Chapter 289 of Singapore and may not be distributed to any other person. This document is being provided for information purposes only. Incorporated in Singapore in 2012, Brandes Investment Partners (Asia) Pte Ltd (Brandes Asia) provides portfolio management services to clients in Asia (as permitted under local law). Brandes Investment Partners, L.P., a U.S. registered investment adviser and a sister entity to Brandes Asia, provides research, portfolio construction and other support to Brandes Asia.

Canada: FOR REGISTERED DEALERS AND THEIR REGISTERED SALESPERSONS' USE ONLY. NOT FOR DISTRIBUTION TO INVESTORS. Distributed by Brandes Investment Partners & Co., 6 Adelaide Street East, Suite 900, Toronto, ON, M5C 1H6. This communication is for information purposes only and should not be regarded as a sales communication or as advice regarding any financial product or services.